Group 1 - Novo Nordisk's stock rose over 6% and Eli Lilly's stock increased nearly 4% due to a lawsuit against Hims & Hers for infringing on the patent of semaglutide [3][4] - Hims & Hers' stock plummeted over 26% after the announcement of the lawsuit, which claimed that their competing product could pose potential dangers to consumers [3][4] - The FDA has indicated it will restrict the use of GLP-1 active ingredients in unapproved compounded drugs, which has been widely sold as alternatives to original drugs [3][4] Group 2 - Analyst Soren Lontoft Hansen from Sydbank noted that the rise in Novo Nordisk's stock reflects investor optimism regarding the FDA's crackdown on the compounded pharmaceutical industry [4] - The FDA's actions are seen as a direct challenge not only to Hims & Hers' compounded oral medication but also to the entire GLP-1 drug sector, benefiting both Novo Nordisk and Eli Lilly [4] - Since peaking in June 2024, Novo Nordisk's market value has evaporated by nearly two-thirds, with a cumulative decline of almost 50% over the past year [4]

| Hims & Hers Health Inc-A (Ai) [ Q | | | --- | --- | | HIMS | | | 16.350 16.923 >> | 17.825 最高 17.900 最低 | | 3.25亿 -26.49% -6.097 快手 | 8.05% 总量 1833万股 金额 | | 盘前 09:30 美东 V | 17.830 -5.190 -22.55% | | 国 年报预披露: 于2026-02-23(美东)盘后披露2025财年年报 ( ... ● | | | 均价:17.712 最新:16.923 -6.097 -26.49% | | | 29.561 | | | 300 9:36 16.950 | | | 9:36 16.950 141 | | | 23.020 - 9:36 16.9601 100 | | | 9:36 16.960 100 | | | 9:36 16.960 125 | | | 100 9:36 16.9234 | | | 9:36 16.940↑ 100 | | | 9:36 16.960↑ 500 | | | -28.42% 9:36 16.9 ...

Investment Rating - The report does not explicitly state the investment rating for Innovent Biologics Core Insights - Innovent Biologics has entered into its seventh global strategic collaboration with Eli Lilly, focusing on the development of innovative drugs in oncology and immunology, with a deal size that exceeds expectations [1][4] - Innovent will lead the R&D work from drug discovery to Proof of Concept (PoC) in China, while retaining all rights in Greater China, which signifies international recognition of its R&D capabilities [2][5] - The collaboration is expected to strengthen Innovent's financial position through an upfront payment of USD 350 million and potential milestone payments of up to approximately USD 8.5 billion [1][4][6] - The focus on oncology and immunology aligns with Innovent's existing core pipeline, enhancing its overall competitiveness [2][6] Summary by Sections Strategic Collaboration - Innovent and Eli Lilly's collaboration will leverage Innovent's mature antibody technology platform and efficient clinical capabilities, reducing overseas development risks while enhancing efficiency through Lilly's global network [2][5] - The collaboration allows Innovent to lead early-stage R&D and retain rights in Greater China, marking a significant step in the globalization of Chinese innovative biopharmaceutical companies [5][6] Financial Implications - The upfront and milestone payments from the collaboration will provide a financial safety net for Innovent, while sales royalties will enable long-term benefits from global market growth [6] - Management projects that Innovent will achieve revenue of CNY 20 billion by 2027, with five products expected to enter MRCT Phase III clinical stages by 2030 [8] Pipeline and Market Potential - Innovent's oncology pipeline is expected to maintain its core market position, with additional growth drivers from integrated pipelines such as Mazdutide, Tolecimab, and Tetumumab [8] - Three assets, including IBI363, IBI343, and IBI324, are set to advance to global multi-regional Phase III clinical stages, with a combined market potential estimated at USD 60 billion [8]

诺和诺德股价延续反弹势头，因远程医疗公司Hims & Hers Health Inc（下称Hims & Hers）迫于监管与法律压力，撤销了推出低价仿制减肥药的计 划。这一消息显著缓解了市场对于诺和诺德核心产品面临廉价仿制药冲击的担忧，巩固了其在GLP-1药物市场的护城河。 监管收紧与竞争对手撤退 Hims & Hers试图推出的这款售价49美元的复合减肥药，其核心成分是司美格鲁肽，这正是诺和诺德旗下重磅药物Wegovy和Ozempic的关键成分。 该产品一发布，便迅速招致了这家丹麦制药商以及监管机构的强烈反对。 据路透社报道，在诺和诺德和FDA发出法律与监管威胁后，Hims & Hers于刚刚过去的周末迅速改变了立场。该公司周六声明称，已决定停止提供 该款治疗药物。这一撤回举动直接推动了诺和诺德在法兰克福股市周一上涨。 在此之前，FDA局长Marty Makary关于打击未经授权复合GLP-1药物的表态，已为市场注入了一剂强心针。这类复合药物一直被视为挑战诺和诺 德在减肥药和糖尿病市场定价权的主要威胁。受此监管风向转变影响，诺和诺德股价在上周五已率先反弹超过5%。 在法兰克福上市的诺和诺德股价周一涨超8%， ...

Group 1 - The core viewpoint of the article highlights that Zhifei Biological (300122.SZ) has one product under review for market launch and multiple products in clinical trials, indicating ongoing development and potential future offerings [1] - An investor inquiry on the interactive platform noted that major pharmaceutical companies Novo Nordisk and Eli Lilly have significantly exceeded performance expectations, with 85% of their sales coming from the Chinese market, raising questions about Zhifei Biological's ability to regain market share and improve its performance once its products are launched [3]

Core Insights - The collaboration between Innovent Biologics and Eli Lilly is valued at over $8.8 billion, marking a significant milestone in the pharmaceutical industry [1][2] - Innovent will receive an upfront payment of $350 million and has the potential to earn up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1][2] - This partnership represents a shift from traditional licensing agreements to a more integrated model involving deep collaboration on technology platforms and research systems [1][2] Group 1 - Innovent will lead the research and development from drug discovery to clinical concept validation in China, while Eli Lilly will have exclusive global development and commercialization rights outside Greater China [3][4] - The collaboration aims to combine Innovent's efficient drug discovery capabilities with Eli Lilly's extensive global reach, creating a synergistic innovation ecosystem [3][4] - The specific number of projects involved in this collaboration has not been disclosed, but it is indicated to be fewer than similar recent partnerships [3][4] Group 2 - Previous collaborations between Chinese pharmaceutical companies and multinational firms have involved a larger number of projects, such as the partnership between CSPC and AstraZeneca, which included eight projects [4] - Innovent's CEO noted that the success of such technology platform collaborations depends on the uniqueness and validation of the platform technology, as well as the contributions to intellectual property from both parties [4] - This marks the seventh collaboration between Innovent and Eli Lilly, indicating a strong existing relationship and mutual understanding [4][5] Group 3 - The trend of multinational companies shifting early-stage research work to China reflects their recognition of the research efficiency and capabilities of Chinese pharmaceutical firms [5] - Innovent achieved product revenues of 11.9 billion yuan in 2025, marking its first time surpassing 10 billion yuan, with a target of reaching 20 billion yuan by 2027 [5]

礼来(LLY.N)盘前上涨2.2%，此前Hims & Hers撤回了减肥药的上市计划。 本文源自：金融界AI电报 ...

2026 年 02 月 09 日 王睿哲 C0062@capital.com.tw 目标价(港币) 98 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/02/06) | | 79.50 | | 恒生指数(2026/02/06) | | 26560.00 | | 股价 12 个月高/低 | | 107.00 / 33.05 | | 总发行股数(百万) | | 1735.19 | | H 股数(百万) | | 1735.19 | | H 市值(亿港币) | | 1379.47 | | 主要股东 | | 俞德超(5.36%) | | 每股净值(港币) | | 9.8324 | | 股价/帐面净值 | | 8.0855 | | | 一个月 三个月 | 一年 | | 股价涨跌(%) | -10.97 -6.69 139.82 | | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/10/22 | 88.00 | 买进 | | 产品组合 | | | --- | --- | | 药品销售 | 87% ...

研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...

2026 年 02 月 09 日 王睿哲 C0062@capital.com.tw 目标价(港币) 98 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/10/22 | 88.00 | 买进 | | 产品组合 | | | --- | --- | | 药品销售 | 87% | | 企业授权产品 | 12% | | 研发收入 | 1% | 股价相对大盘走势 C o m p a n y U p d a t e C h i n a R e s e a r c h D e p t . 信达生物 (01801.HK) 买进（Buy） 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/02/06) | | 79.50 | | 恒生指数(2026/02/06) | | 26560.00 | | 股价 12 个月高/低 | | 107.00 / 33.05 | | 总发行股数(百万) | | 1735.19 | | H 股数(百万) | | 1735.19 | | H 市值(亿港币) | | 1379.47 ...